Cover Image

Patients with advanced pancreatic cancer treated with mistletoe and hyperthermia in addition to palliative chemotherapy: a retrospective single-center analysis

This retrospective analysis investigated the influence of integrative therapies in addition to palliative chemotherapy in patients with advanced pancreatic cancer, treated at a single institution specialized in integrative oncology between January 2015 and December 2019. In total, 206 consecutive pa...

Full description

Saved in:
Bibliographic Details
Main Authors: Hohneck, Anna (Author) , Sadikaj, Largsi (Author) , Heinemann, Lara (Author) , Schroeder, Maik (Author) , Riess, Hartmut (Author) , Gerhards, Annette (Author) , Burkholder, Iris (Author) , Heckel-Reusser, Stefan (Author) , Gottfried, Julia (Author) , Hofheinz, Ralf-Dieter (Author)
Format: Article (Journal)
Language:English
Published: 11 October 2023
In: Cancers
Year: 2023, Volume: 15, Issue: 20, Pages: 1-15
ISSN:2072-6694
DOI:10.3390/cancers15204929
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/cancers15204929
Verlag, kostenfrei, Volltext: https://www.mdpi.com/2072-6694/15/20/4929
Get full text
Author Notes:Anna Lena Hohneck, Largsi Sadikaj, Lara Heinemann, Maik Schroeder, Hartmut Riess, Annette Gerhards, Iris Burkholder, Stefan Heckel-Reusser, Julia Gottfried and Ralf-Dieter Hofheinz
Description
Summary:This retrospective analysis investigated the influence of integrative therapies in addition to palliative chemotherapy in patients with advanced pancreatic cancer, treated at a single institution specialized in integrative oncology between January 2015 and December 2019. In total, 206 consecutive patients were included in the study, whereof 142 patients (68.9%) received palliative chemotherapy (gemcitabine/nab-paclitaxel 33.8%; FOLFIRINOX 35.9%; gemcitabine 30.3%) while the remainder were treated with best supportive and integrative care. Integrative therapies were used in 117 of 142 patients (82.4%) in addition to conventional chemotherapy, whereby mistletoe was used in 117 patients (82.4%) and hyperthermia in 74 patients (52.1%). A total of 107/142 patients (86.3%) died during the observation period, whereby survival times differed significantly depending on the additional use of integrative mistletoe or hyperthermia: chemotherapy alone 8.6 months (95% CI 4.7-15.4), chemotherapy and only mistletoe therapy 11.2 months (95% CI 7.1-14.2), or a combination of chemotherapy with mistletoe and hyperthermia 18.9 months (95% CI 15.2-24.5). While the survival times observed for patients with advanced pancreatic cancer receiving chemotherapy alone are consistent with pivotal phase-III studies and German registry data, we found significantly improved survival using additional mistletoe and/or hyperthermia.
Item Description:Gesehen am 22.07.2024
Physical Description:Online Resource
ISSN:2072-6694
DOI:10.3390/cancers15204929

Similar Items